drugset / Trial / NCT01313273
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer patients.
Timeline
- Start
- 2011-06
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanreotide | Other / unclassified | 120 mg | Other |
| Background | Bicalutamide | Other / unclassified | 50 mg | — |
| Background | Triptorelin | Other / unclassified | 3.75 mg | — |